

SAIS NEWSLETTER – FEBRUARY 25th 2022

Dear SAIS

Find this week's newsletter below. I warmly welcome all members to send me their publications for inclusion in the next newsletter. Follow us on our social media platforms – SAIS LinkedIn, Facebook and Twitter pages for daily updates. Also, we warmly welcome **Thanusha Pillay** into the Newsletter publication team. Thanusha, we hope to enjoy your vast experience in Newsletters to improve SAIS communications.

Newsletters team

FUNDING CALLS, CONFERENCES, WEBINARS and ANNOUNCEMENTS



OPTIMMUNIZE WEBINAR
Non-specific effects of vaccines in a COVID-19 context

21 April 2022, from 12-16 CET.
Register at:
<https://event.sdu.dk/pre-conference-webinar>

We will learn of the first results of trials initiated to test non-specific effects of vaccines, such as BCG, oral polio vaccine and measles-containing vaccine, against COVID-19.

CONFIRMED SPEAKERS

 <p>Andreas Diacon, South Africa trial</p>	 <p>Mihai Netea, Netherlands trial</p>
 <p>Evangelos Giamarellos-Bourboulis Greece trial</p>	 <p>Denise Faustman, U.S.A trial</p>
 <p>Ane Fisker, Guinea-Bissau trial</p>	

ORGANIZING COMMITTEE
Christine Stabell Benn, Jorge Dominguez-Andres, Eleanor Fish, Katie Flanagan, Sabra Klein, Tobias Kollmann, Frederik Scholtz-Buchholzer.



#ENDTB WEBINAR

TUBERCULOSIS PREVENTION AND CARE AMONG REFUGEES AND OTHER POPULATIONS IN HUMANITARIAN SETTINGS

MARCH 2, 2022
13:30H-15:00H CET



For more information and registration, please visit <https://www.tbonline.info/posts/2022/2/21/who-endtb-webinar-tb-prevention-and-care-among-ref/>

PUBLICATIONS and INTERESTING READS

Association of SARS-CoV-2 Infection With Serious Obstetric Complications

https://www.practiceupdate.com/c/131704/1/20/?elsca1=emc_eneews_expert-insight&elsca2=email&elsca3=practiceupdate_rm&elsca4=respiratorymedicine&elsca5=newsletter&rid=NDY1Mzc5NzcwNTYyS0&lid=22920208

Booster in Immunosuppressed Patients Without Seroconversion After Initial mRNA Vaccine

https://www.practiceupdate.com/c/131020/75/24/?elsca1=emc_eneews_weekinreview&elsca2=email&elsca3=practiceupdate_cv19&elsca4=cv19&elsca5=newsletter&rid=NDY1Mzc5NzcwNTYyS0&lid=31048597

False-Positive Results in Rapid Antigen Tests for SARS-CoV-2

<https://www.practiceupdate.com/content/false-positive-results-in-rapid-antigen-tests-for-sars-cov-2/131497/15/24/1>

Fewer Pills Plus Shorter Time: New Way to Control Drug-Resistant TB?

<https://www.medpagetoday.com/meetingcoverage/croi/97243>

Third Person 'Cured' of HIV via Transplant

<https://www.medpagetoday.com/meetingcoverage/croi/97217>

COVID Makes Everything Worse in Pregnancy

<https://www.medpagetoday.com/meetingcoverage/croi/97250>

Starting antiretroviral therapy early essential to battling not one, but two killers

<https://www.tbonline.info/posts/2022/2/15/starting-antiretroviral-therapy-early-essential-ba/>

Analysis of DNA reveals weapons used by our immune cells to fight TB

<https://www.tbonline.info/posts/2022/2/21/analysis-dna-reveals-weapons-used-our-immune-cells/>

Interactions between COVID-19 and Malaria

<https://www.frontiersin.org/research-topics/31408/interactions-between-covid-19-and-malaria>

Lung microbes mediate spinal-cord autoimmunity

<https://www.nature.com/articles/d41586-022-00468-x>

JOBS and POSITIONS

Regional Medical Liaison - HVTN, Cape Town

The HIV Vaccine Trials Network (HVTN) is the world's largest publicly funded multi-disciplinary international collaboration facilitating the development of vaccines to prevent HIV/AIDS. Most recently, the COVID-19 Prevention Network (CoVPN) was formed by the National Institute of Allergy and Infectious Diseases (NIAID) at the US National Institutes of Health to respond to the global pandemic. The mission of CoVPN is to conduct Phase 3 Efficacy Trials to prevent infection and COVID19 disease.

The Regional Medical Liaison plays a key role in providing clinical support for clinical research sites (CRSs) implementing vaccine & prevention trials of the HVTN/CoVPN in Southern Africa.

Qualification: A medical doctor (MBChB, MBBS, MD or equivalent degree) with clinical experience in Southern Africa is strongly preferred. Please submit a direct email to Bongi Vilakazi (svilakaz@hcrisa.org.za) or check the online application via <https://southafrica-fhcr.icims.com/jobs/search>

CHIL Research Operations Manager – HVTN, Cape Town

This position manages operational aspects of laboratory and clinical research studies, liaising with external collaborators, stakeholders and key personnel in the lab and clinic.

Qualification: PhD and at least 5 years of postdoctoral experience in a related field required. Please email Bongi Vilakazi (svilakaz@hcrisa.org.za) with your application or check <https://southafrica-fhcr.icims.com/jobs/search>.

Research Technologist I– HVTN, Cape Town

The purpose of this position is to perform laboratory technical work to assess immune responses.

Qualification: BSc, BHSc, BTech or MedTech, MSc or MTech with at least 2 years of wet lab experience in immunology, molecular biology, virology, or related field. Submit a detailed CV to: svilakaz@hcrisa.org.za or apply online <https://southafrica-fhcr.icims.com/jobs/search>.

IMPORTANT LINKS

To renew your SAIS Membership please visit: <https://saimmunology.org.za/membership.htm>

If you are recruiting/hiring, we are more than happy to advertise it in the newsletters and on Social Media platforms. Please send information to Clement - clementgascua@yahoo.com and clementa@nicd.ac.za